Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Department of Hematology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
Chest. 2019 Jan;155(1):e1-e4. doi: 10.1016/j.chest.2018.08.1052.
Bronchiolitis obliterans (BO) is a significant life-threatening complication that occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is associated with increased morbidity and mortality. BO responds poorly to corticosteroids or immunosuppressants, and there are currently no established treatment approaches. We herein describe a patient with biopsy-proven BO after allo-HSCT who was successfully treated with tamibarotene, a novel synthetic retinobenzoic acid. Tamibarotene led to a dramatic improvement in lung function as well as cutaneous manifestations of chronic graft-vs-host disease. A large prospective clinical trial is therefore warranted to confirm the efficacy of tamibarotene in BO.
闭塞性细支气管炎（BO）是异基因造血干细胞移植（allo-HSCT）后发生的一种严重危及生命的并发症，与发病率和死亡率增加有关。BO 对皮质类固醇或免疫抑制剂反应不佳，目前尚无既定的治疗方法。本文描述了一例 allo-HSCT 后经活检证实为 BO 的患者，该患者使用新型合成视黄酸他米巴罗汀成功治疗。他米巴罗汀使肺功能以及慢性移植物抗宿主病的皮肤表现显著改善。因此，有必要进行大型前瞻性临床试验来确认他米巴罗汀治疗 BO 的疗效。
